The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer
- 1 March 2005
- journal article
- research article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 31 (2) , 164-169
- https://doi.org/10.1016/j.ejso.2004.09.007
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Serum Tumor Markers and Molecular Biological Diagnosis in Pancreatic CancerPancreas, 2004
- Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors.International Journal of Oncology, 2004
- MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspirationCancer, 2003
- A clinical evaluation of serological diagnosis for pancreatic cancer*World Journal of Gastroenterology, 1998
- CAM 17.1 - A new diagnostic marker in pancreatic cancerBritish Journal of Cancer, 1996
- Altered expression of MUC2, MUC4, and MUC5 mucin genes in pancreas tissues and cancer cell linesGastroenterology, 1994
- A carbohydrate domain common to both sialyl Le(a) and sialyl Le(X) is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1Journal of Biological Chemistry, 1991
- Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion moleculePublished by Elsevier ,1989
- Tumour marker antigen CA125 in pancreatic cancer: A comparison with CA19-9 and CEABritish Journal of Cancer, 1986